GleamWall
中文EN

DERM Journey Medical Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1867066 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.0%
TTM net income YoY41.1%
TTM EPS YoY48.6%
Revenue 3-yr CAGR-4.5%
Net income 3-yr CAGR—

Margins

Gross margin65.9%
Operating margin-2.9%
Net margin-7.3%
FCF margin—
EBITDA margin—

Returns

ROE-17.6%
ROA-5.4%
ROIC (approx.)-5.2%
Asset turnover0.74x

Leverage & solvency

Liabilities / assets68.9%
Debt / equity0.79x
Current ratio1.48x
Interest coverage-0.55x

Cash quality & payout

Operating cash flow / net income1.67x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$61.86M$56.13M
Cost of revenue$20.92M$20.88M
Gross profit$40.93M$35.26M
R&D expense$480,000$9.86M
SG&A expense$44.37M$40.20M
Operating income-$8.17M-$13.68M
Interest expense$3.70M$2.70M
Pretax income-$11.37M-$14.61M
Income tax$60,000$61,000
Net income-$11.43M-$14.67M
EPS (basic)-0.47-0.72
EPS (diluted)-0.47-0.72
Weighted avg. shares (diluted)24.50M20.43M
Balance sheet
Cash & equivalents$24.09M$20.30M
Receivables$29.78M$10.23M
Inventory$9.62M$14.43M
Current assets$66.87M$48.18M
Intangibles$27.61M$31.86M
Total assets$94.59M$80.24M
Current liabilities$37.44M$35.17M
Long-term debt$25.28M$24.88M
Total debt$25.28M$24.88M
Total liabilities$62.74M$60.17M
Shareholders' equity$31.85M$20.07M
Net debt$1.19M$4.57M
Cash flow statement
Operating cash flow-$12.44M-$9.13M
Capital expenditure—$15.00M
Free cash flow—-$24.13M
Investing cash flow—-$15.00M
Financing cash flow$16.23M$16.99M
Stock-based compensation$6.29M$6.10M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.